0001567619-22-001225.txt : 20220114 0001567619-22-001225.hdr.sgml : 20220114 20220114204551 ACCESSION NUMBER: 0001567619-22-001225 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211221 FILED AS OF DATE: 20220114 DATE AS OF CHANGE: 20220114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 22533319 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2021-12-21 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer Common Stock 2021-12-21 4 L 0 100 89.2246 A 303789 D Common Stock 2022-01-12 4 M 0 5000 37.46 A 308789 D Common Stock 2022-01-12 4 S 0 5000 89.00 D 303789 D Common Stock 2022-01-13 4 M 0 5000 37.46 A 308789 D Common Stock 2022-01-13 4 S 0 5000 87.86 D 303789 D Common Stock 247533 I Shares held by Jean-Jacques Bienaime Family Trust Stock Option (Right to buy Common Stock) 37.46 2022-01-12 4 M 0 5000 0 D 2012-11-08 2022-05-07 Common Stock 5000 120000 D Stock Option (Right to buy Common Stock) 37.46 2022-01-13 4 M 0 5000 0 D 2012-11-08 2022-05-07 Common Stock 5000 115000 D Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's purchase of shares at a price of $78.7700 on September 9, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Eric Fleekop, Attorney-in-Fact 2022-01-14